Loss of Cardiomyocyte Janus Kinase 1 (Jak1) Causes Cardiomyopathy
Journal of Molecular and Cellular Cardiology PlusArasakumar Subramani +4 more
doaj +2 more sources
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs
Molecular & Cellular Oncology, 2021 While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder +2 more
doaj +1 more source
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis [PDF]
Brain, 2019 Papadopoulou, C +4 more
openaire +4 more sources
Pharmacology of inhibitors of Janus kinases – Part 1: Pharmacokinetics
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2022 SummaryThe use of Janus kinase inhibitors for the treatment of chronic inflammatory diseases is increasingly establishing itself as a treatment option for several indications. In order to make clinical use efficient, pharmacological knowledge of the JAK/STAT signaling pathway and the special features of the pharmacokinetics of the individual drugs is ...
Adina, Eichner, Johannes, Wohlrab
openaire +2 more sources
Peripheral neuropathy associated with tofacitinib use in alopecia universalis
Journal of Dermatology and Dermatologic Surgery, 2022 Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. Alopecia universalis (AU) is the advanced form of AA characterized by complete scalp and body hair loss.
Raghad Alharthi +4 more
doaj +1 more source
Janus Kinase Inhibitors: Safety in Patients With Psoriatic Arthritis
, 2022 Janus kinase inhibitors (JAKi; or Jakinibs) have become widely prescribed around the world for a variety of immune-mediated inflammatory diseases, including psoriatic arthritis.
Nash, P
core +1 more source
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
Cochrane Database of Systematic Reviews, 2015 Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J, Martí-Carvajal +2 more
openaire +4 more sources
Generation of Janus kinase 1 (JAK1) conditional knockout mice [PDF]
genesis, 2016 AbstractThe biological functions of the Janus kinase 1 (JAK1) are suggested to be pleiotropic since this signal transducer is ubiquitously expressed and coupled to a variety of cytokine receptors. Consequently, mice that are deficient in this tyrosine kinase were reported to die shortly after birth. To facilitate studies that address the biological and
Kazuhito, Sakamoto +4 more
openaire +2 more sources
Constitutive nuclear localization of Janus kinases 1 and 2. [PDF]
Endocrinology, 1996 Both GH and the GH receptor have been reported to undergo rapid nuclear translocation. Janus kinases (JAK) 1 and 2 have been implicated in GH receptor signaling, and both of these kinases are phosphorylated by GH stimulation. In this report, we have investigated the subcellular distribution of JAK1 and JAK2.
Lobie, P.E. +5 more
openaire +2 more sources
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals [PDF]
, 2021 Janus kinase (JAK) inhibitors for the treatment of hospitalised patients with COVID-19 have been extensively studied. Initially, at the start of the pandemic outside of China, baricitinib was shown using artificial intelligence to have a potential dual ...
Kruglova, Tatiana +19 more
core +2 more sources